Loading...
NPI 1124075635 · Nashville, TN · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Associated Pathologists LLC is a clinical medical laboratory provider located in Nashville, Tennessee. This profile covers 16 Medicare and 114 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Associated Pathologists LLC |
| Address | 1010 Airpark Center Dr |
| City | Nashville |
| State | TN |
| ZIP | 37217 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | May 28, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $27.8M |
| Medicare | $2.7M |
Associated Pathologists LLC has been an active, enumerated Clinical Medical Laboratory for about 20 years (NPI enumerated: 2006-05-28), indicating an established presence in Nashville with sustained operations over two decades. This tenure supports the scale of services reflected in both Medicare and Medicaid billing mixes.
Medicaid dominates the public payer revenue mix: total Medicaid revenue is $27.8M versus total Medicare revenue of $2.7M, indicating the provider is effectively Medicaid-first in scale and volume. Analysts should treat this entity as a major Medicaid billing source rather than a Medicare-focused lab.
Medicare revenue is highly concentrated: the top 3 Medicare codes account for 93.4% of the provider’s Medicare revenue, led by 81479 which alone generates $2.1M (77.7% of Medicare revenue). This concentration shows the provider’s Medicare business is driven almost entirely by high-revenue molecular pathology testing rather than a broad set of routine lab services.
By contrast, Medicaid revenue is more distributed: the top 3 Medicaid codes account for 39.4% of Medicaid revenue, with large volumes across infectious disease and molecular test codes such as U0003, 87491, and 87591. This mix suggests a high-throughput clinical testing operation focused on infectious disease screening and diagnostic panels for the Medicaid population.
Competitive standing differs by payer and code set. For Medicare molecular testing, the provider’s rank on 81479 is #18 of 80 (78th percentile), which indicates a typical, unremarkable national volume rather than market dominance. For other Medicare genetic tests (e.g., 81450 ranks #7 of 48, 87th percentile), the provider shows relatively higher positioning but still within routine peer ranges.
In the Medicaid market the provider is a clear high-volume outlier for several infectious disease and COVID-era codes. U0003 is ranked #4 of 95 in-state (97th percentile) and labeled an “extreme outlier, far above typical state volume,” while 87801 is #1 of 19 in-state (100th percentile) and also an extreme outlier. Multiple STD/nucleic-acid codes (87491, 87591, 87661) sit at or above the 97th percentile in-state, indicating this lab is a major state-level supplier of nucleic-acid testing services.
Service-line implications: the code mix reflects a dual focus on high-complexity molecular/genomic testing for Medicare (e.g., 81479, 81450, 81219) and very large-volume infectious disease/STD and COVID testing under Medicaid (e.g., U0003, 87491, 87591, 87661). Operationally, this pattern is consistent with a lab that combines specialty molecular diagnostics with high-throughput public health and screening workflows.
Several Medicaid procedure codes are flagged as exceptional volume in-state beyond typical peers: 88175 (cervical cytology technical component), U0005, 87633 (respiratory virus panels), and 36415 (phlebotomy) also rank at very high percentiles including multiple 97–100th percentile positions and are labeled extreme outlier or notably above typical. These signals suggest broad contracted relationships with public programs or large specimen-processing capacity statewide.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
16 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81479 | Use 81479 to report a molecular pathology procedure that does not have a specific code. | 1,020 | $2,020 | $2.1M |
| 81450 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen, such as blood or bone marrow, for DNA and possibly RNA alterations in five to 50 genes known to impact… | 490 | $740 | $367.5K |
| 81219 | The lab analyst performs the technical lab test to analyze common exon 9 variants for the CALR (calreticulin) gene. | 400 | $120 | $48K |
| 81206 | The lab analyst performs the technical lab test to evaluate the major breakpoint gene sequence BCR/ALB1 that occurs on chromosome 22 due to translocation, which involves breakage and reforming of an… | 290 | $160 | $46.7K |
| 81301 | The lab analyst performs the technical lab test to detect the presence of microsatellite instability, also known as MSI, in tumor cells from tissue specimens such as colon cancer. | 90 | $340 | $29.8K |
| 81263 | The lab analyst performs the technical lab test to analyze for mutations in the VH or variable region of the Immunoglobulin heavy chain locus, also known as IGH@. | 80 | $290 | $23.4K |
| 81256 | The lab analyst performs the technical lab test to detect the presence of common changes in the hemochromatosis gene, also known as HFE. | 240 | $60 | $15K |
| 81374 | The lab analyst performs the technical lab test for low or intermediate resolution assessment of human leukocyte antigen genes, called HLA, for one Class I antigen equivalent, which is an allele… | 170 | $70 | $12.5K |
| 81270 | The lab analyst performs the technical lab test to detect the presence of a common change in the gene for Janus kinase 2, also known as JAK2. | 130 | $90 | $11.3K |
| 81288 | The lab analyst performs the technical lab test involving promoter methylation analysis to detect changes for the mutL homolog 1, or MLH1 gene, also known as the colon cancer or nonpolyposis type 2… | 50 | $190 | $9.2K |
Showing 1–10 of 16
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 16 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
114 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 93,800 | $60 | $5.7M |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 116,030 | $20 | $2.4M |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 114,560 | $20 | $2.4M |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 107,340 | $20 | $2.3M |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 38,150 | $50 | $1.8M |
| 88175 | The lab analyst performs the technical lab test to analyze a cervical or vaginal cytopathology specimen that a clinician collected in preservative fluid. The test uses automated thin layer… | 87,010 | $20 | $1.5M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 68,990 | $20 | $1.2M |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 76,570 | $20 | $1.1M |
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 19,230 | $60 | $1.1M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 48,310 | $20 | $917.8K |
Showing 1–10 of 114
How this provider's Medicaid billing volume and revenue compare to other Tennessee providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Tennessee median
114 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 81420 | The lab analyst performs a genomic sequence analysis panel to evaluate circulating cell free fetal DNA in maternal blood for genetic sequences of at least the genes on chromosomes 13, 18, and 21,… | 3 | 10 | 3,970 | $220 | $843K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 4 | 100 | 400 | $60 | $524.7K |
| 88185 | The lab analyst performs the technical component of a flow cytometry procedure using cell surface, cytoplasmic, or nuclear markers to characterize cells and aid clinicians in diagnosing patients with… | 5 | 10 | 770 | $140 | $500.5K |
| 81220 | The lab analyst performs the technical lab test to detect the presence of changes in the gene for cystic fibrosis transmembrane conductance regulator, also known as CFTR. The test evaluates the CFTR… | 4 | 10 | 210 | $200 | $285.2K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 2 | 30 | 480 | $20 | $283.4K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 106 | 240 | 840 | $20 | $259.2K |
| 88175 | The lab analyst performs the technical lab test to analyze a cervical or vaginal cytopathology specimen that a clinician collected in preservative fluid. The test uses automated thin layer… | 2 | 30 | 700 | $10 | $227.5K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 3 | 70 | 250 | $20 | $215.6K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 3 | 70 | 270 | $20 | $215.5K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 2 | 20 | 190 | $10 | $192.8K |
Showing 1–10 of 114
Other providers in the same ZIP code as Associated Pathologists LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.